Compare Amphastar Pharmaceuticals Inc (AMPH) vs Manhattan Associates Inc (MANH) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

MANH trades at $154.9, down 1.1% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company maintains strong profitability with a 19.68% net margin and has beaten earnings estimates for three consecutive quarters. Recent news is dominated by an ongoing legal investigation into fiduciary duties by directors and officers.

The outlook is supported by a strong analyst consensus 'Buy' rating and a $192.80 price target, implying significant upside. Key risks include the legal investigation's outcome and potential pressure on valuation multiples, which are elevated. Revenue stability and high ROE of 96.24% underpin the fundamental case.